Healthcare

AVITA is unusual among ASX-listed biotechs: it is a US-domiciled company, headquartered in California, whose primary operations and revenue are in the United States, and which is also listed on the Nasdaq under "RCEL". Its reported financial figures are in US dollars.

A stronger trading session is noteworthy, but for Paradigm it comes at a consequential moment: the company has completed enrolment in its pivotal Phase 3 osteoarthritis trial and has guided investors toward an interim analysis around the middle of 2026. That readout is widely …

The decline should be read in context. Amplia had been one of the ASX biotechnology sector's stronger performers over the prior year, its market value rising sharply on clinical progress in pancreatic cancer. Against that backdrop, a single-session dip of a few per cent …

A modest gain is not unusual for a small-cap developmental biotech between major updates. For Prescient, the more meaningful story is the steady progress of its lead drug, PTX-100, through a global Phase 2a trial, alongside two earlier-stage cell-therapy platforms that give the company …

A decline of just under 4% is a modest single-session move, particularly for a small-cap medical-diagnostics stock where day-to-day volatility is common. It follows a period in which Cleo has reported a steady stream of clinical and regulatory milestones, so a small pullback may …

At a share price of two cents, a one-tick move produces a large percentage change, and a stock at such a low absolute price can swing sharply on modest turnover, sentiment or momentum. Radiopharm sits within nuclear medicine, an area attracting growing investor and …

The surge is notable because Mesoblast spent much of its two-decade history as a clinical-stage company burning cash in pursuit of approval. That changed in December 2024, when Ryoncil became the first mesenchymal stromal cell (MSC) therapy approved by the US Food and Drug …